Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the data from this study will be fully interpreted or will be submitted to medical meetings in the future. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Rebecca Gregory, Corporate Communications of ImClone SystemsIncorporated, +1-646-638-5058, ; or Media, Madeline Malia,+1-609-252-3347, , or Tony Plohoros, +1-609-252-7938,, or Investors, John Elicker, +1-212-546-3775,, all of Bristol-Myers Squibb media@imclone.com Madeline.Malia@bms.com tony.plohoros@bms.com John.Elicker@bms.com

Web site: http://www.bms.com/http://www.ERBITUX.com/

Ticker Symbol: (NYSE:BMY),(NASDAQ-NMS:IMCL)

Terms and conditions of use apply
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/31/2015)... 31, 2015 Research and Markets ( ... "Prescription Pain Drugs - Including Opioid, Anticonvulsant, ... Markets, Competitors and Opportunities: 2015 - 2020 Analysis ... Pain is defined as an unpleasant ... potential tissue damage. At some point, everyone experiences ...
(Date:8/29/2015)... y LONDRES, August 29, 2015 ... para los sistemas de imagen por Ultrasonidos ... Ecografía, tiempos de examen rápidos y un flujo de ... confianza diagnóstica en el proceso de detección de Cardiopatías ... PHIA) ha anunciado hoy el lanzamiento europeo de ...
(Date:8/28/2015)... Calif. , Aug. 28, 2015  CytomX Therapeutics, ... treatment of cancer, today announced the filing of a ... and Exchange Commission (SEC) relating to a proposed initial ... shares to be offered and the price range for ... to list its common stock under the symbol "CTMX" ...
Breaking Medicine Technology:Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5CytomX Files Registration Statement for Proposed Initial Public Offering 2
... Dec. 4 Long-term data published in,EuroIntervention showed ... (MVA),after repair with the MitraClip(R) system to correct ... mitral stenosis. Additionally,with two years of follow-up, none ... surgery for mitral stenosis. At 12 months no,important ...
... newly diagnosed patients with a life-threatening type of leukemia to be ... , - Exjade results at ASH to show benefits ... damage key organs , , - ... to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen , ...
Cached Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
(Date:8/31/2015)... ... 31, 2015 , ... The Foundation for Women’s Cancer ... about the role of heredity in below-the-belt gynecologic cancers. , Considerable media ... Pitt’s decisions to have both her breasts and ovaries removed to prevent breast ...
(Date:8/31/2015)... ... August 31, 2015 , ... Move over shave cream. Roll over beard ... are scrambling to meet it. , Reports published this year (Mintel data) announced that ... the data also reflects that men are getting more done at barbershops than a ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... MeYou ... recently enhanced its mobile walking app, Walkadoo , by including an in-app step ... goals that adapt to each person’s walking habits. Rather than broadly assign every Walkadoo ...
(Date:8/31/2015)... ... 2015 , ... Juvent Sports ( http://www.juvent.com ) just announced the addition of ... finding joint pain relief after using their revolutionary Micro-Impact Platform™ . Wilander, winner ... said, “For the first time in over 20 years I am joint pain free. ...
(Date:8/31/2015)... , ... August 31, 2015 , ... According to book ... Solution: Taking Charge of Your Life with Cancer is an excellent resource for ... found The Cancer Solution to be helpful in explaining what cancer is in a ...
Breaking Medicine News(10 mins):Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2
... Worksite wellness programs are a proven strategy ... disease, according to a policy statement published today ... Association . These risk factors include smoking, overweight, ... , To view the Multimedia News Release, go ...
... Information Services, a national provider of full-service medical transcription ... Chief Executive Officer. Previously Chief Operating Officer and Chief ... position immediately. , Himes will be taking over for ... new position with Reichert, Inc. Reichert is owned by ...
... health cuts medical costs and ups productivity, heart experts ... wellness programs are an effective way to reduce major ... high blood pressure and diabetes, says a new American ... disease costs the United States about $304.6 billion, the ...
... YORK (Sept. 30, 2009) -- New research by Weill ... parents and peers influence teenagers to smoke, drink and ... smoking influenced teenagers, use of multiple drugs (smoking, drinking ... boys and girls. For girls, friends were shown ...
... People who suffer from debilitating neuropathic pain may ... commonly-prescribed drugs. A new, federally-funded study by ... together is a more effective treatment than taking either ... drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from ...
... system made of billions of neurons and thousands of ... of the strongest emotions, fear. Most neurological fear studies ... Missouri researchers have started using computational models of the ... Guoshi Li, an electrical and computer engineering doctoral student, ...
Cached Medicine News:Health News:Video: Worksite Wellness Programs Lower Healthcare Costs, Make Employees Healthier 2Health News:Video: Worksite Wellness Programs Lower Healthcare Costs, Make Employees Healthier 3Health News:Video: Worksite Wellness Programs Lower Healthcare Costs, Make Employees Healthier 4Health News:Heartland Information Services Appoints New Chief Executive Officer 2Health News:Workplace Wellness Seems to Really Work 2Health News:Teen attitudes toward smoking linked to likelihood of drinking and using drugs 2Health News:Chronic pain treatments work better together, says anesthesiologist 2Health News:Researchers use computational models to study fear 2
... Codman ICP Monitoring System ... of intracranial pressure at ... intraventricular levels. The information ... than through a hydrostatic ...
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)...
Penfield Dissector #1...
Raney scalp clip system includes Raney scalp clips made of metal and plastic with atraumatic design. The plastic clips are disposable while the metal clips are reusable....
Medicine Products: